Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 391-395

  Krejci, Pavel ^a,b,c   Pejchalova, Katerina ^a   Wilcox, William R ^a,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MASARYK UNIVERSITY   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erk; FGFR3; Growth arrest; Inhibitor; Library; Screening

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL COUNT; CELL GROWTH; CHONDROSARCOMA; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; RATS;

EID: 34250682188     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9054-7     Document Type: Article

References (17)

1. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J (1993) Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90:8319-8323
2. Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726-735
3. Cowley S, Paterson H, Kemp P, Marshall CJ (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77:841-852
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave B, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
5. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462
6. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2511
7. Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D (2006) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866-873
8. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere R, Herrera R, Sebolt-Leopold J, Meyer MB (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281-5293
9. Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350-356
10. Mukhopadhyay K, Lefebvre V, Zhou G, Garofalo S, Kimura JH, De Crombrugghe B (1995) Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. J Biol Chem 270:27711-27719
11. Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, Wilcox WR (2004) FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res 297:152-164
12. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis MA, Prats H, Wilcox WR (2005) Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118:5089-5099
13. Raucci A, Laplantine E, Mansukhani A, Basilico C (2004) Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem 279:1747-1756
14. Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Michels Thompson L, Wilcox WR (2007) Bisindolylmaleimide I suppresses FGF-mediated activation of ERK map kinase in chondrocytes by preventing SHP2 association with the FRS2 and GAB1 adaptor proteins. J Biol Chem 282:2929-2936
15. Roovers K, Assoian RK (2000) Integrating the MAP kinase signal into the G1 phase cell cycle machinery. BioEssays 22:818-826
16. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73
17. L'Hote CG, Knowles MA (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304:417-431